中高危分化型甲状腺癌当前131I辅助治疗指征的反思性分析
该多中心回顾性研究纳入3个中心599例中高危分化型甲状腺癌患者,评估术后疾病状态、实时目的验证及131I辅助治疗12个月反应。术后49.75%为极好反应/不确定反应,37.56%为生化不完全反应,12.69%为结构不完全反应;12个月最终反应分别为59.39%、13.48%、16.55%和10.58%。作者认为术后极好反应或不确定反应的中危患者或可免除激进辅助治疗,而术后生化不完全反应患者可能是较高给药活度辅助治疗的潜在候选者。
要点
- 599例中高危分化型甲状腺癌患者中,术后49.75%为极好反应/不确定反应,37.56%为生化不完全反应,12.69%为结构不完全反应。
- 术后极好反应/不确定反应患者中95.64%在12个月维持极好反应/不确定反应;术后生化不完全反应患者中45.78%转为极好反应/不确定反应。
- 作者认为术后极好反应或不确定反应的中危患者或可免除激进辅助治疗,术后生化不完全反应患者可能是较高给药活度辅助治疗的潜在候选者。
核心结论
- 作者认为术后极好反应或不确定反应的中危患者或可免除激进的131I辅助治疗。
- 作者认为术后生化不完全反应患者可能是较高给药活度(>3.7 GBq,中位5.55 GBq,IQR 4.625 GBq-5.55 GBq)131I辅助治疗的潜在候选者,尤其是临床病理特征侵袭性较低、可能在12个月反应中获得极好反应/不确定反应者。
研究设计与样本
- 多中心回顾性研究,纳入来自3个中心的599例中高危分化型甲状腺癌患者。
- 通过随访中的甲状腺球蛋白水平、影像学及治疗后全身扫描评估术后疾病状态、实时目的验证及131I辅助治疗12个月反应。
主要发现
- 术后疾病状态:49.75%为极好反应/不确定反应,37.56%为生化不完全反应,12.69%为结构不完全反应。
- 实时目的验证:49.92%靶向残留甲状腺,36.73%靶向生化疾病,13.36%靶向结构/功能性疾病。
- 12个月最终反应:59.39%为极好反应,13.48%为不确定反应,16.55%为生化不完全反应,10.58%为结构不完全反应。
- 术后极好反应/不确定反应患者中95.64%在12个月维持极好反应/不确定反应;术后生化不完全反应患者中45.78%转为极好反应/不确定反应。
- 中危、T1/T2分期、无甲状腺包膜侵犯、非多灶病变、手术次数、治疗后全身扫描无异常发现是术后生化不完全反应转为12个月极好反应/不确定反应的预测因素(均P < 0.05)。
关键数值与推荐
- 术后生化不完全反应转为12个月极好反应/不确定反应的预测因素包括中危、T1/T2分期、无甲状腺包膜侵犯、非多灶病变、手术次数及治疗后全身扫描无异常发现(均P < 0.05)。
- 作者提出较高给药活度为>3.7 GBq,中位5.55 GBq,IQR 4.625 GBq-5.55 GBq。
临床怎么用
- 作者认为术后极好反应或不确定反应的中危患者或可免除激进的131I辅助治疗。
- 作者认为术后生化不完全反应患者可能是较高给药活度131I辅助治疗的潜在候选者,尤其是临床病理特征侵袭性较低者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radioiodine (131I) adjuvant therapy (RAT) is given to treat subclinical tumor of differentiated thyroid cancer (DTC) that may or may not actually be present after prior adequate treatment, yet the indications and benefits for RAT remain controversial. This multi-center study retrospectively evaluated the real targets and responses to RAT in intermediate- and high-risk patients, aiming to refine current "one-size-fits-all" guidelines. METHODS: Totally 599 intermediate- and high-risk DTC patients from three centers were enrolled. The post-operative disease status, instant purpose verification and 12-month response to RAT were assessed using thyroglobulin levels, imagings and post-therapy whole-body scan (Rx-WBS) during follow-ups. RESULTS: Totally 49.75% patients were assessed as post-operative disease status excellent response (ER)/indeterminate response (IDR), 37.56% patients were biochemical incomplete response (BIR) and 12.69% were structural incomplete response (SIR). Through instant purpose verification, 49.92%, 36.73%, and 13.36% patients were targeted at remnant thyroid, biochemical and structural/functional disease, respectively. 59.39%, 13.48%, 16.55%, and 10.58% patients were ER, IDR, BIR and SIR at 12-month final response, respectively. 95.64% patients with post-operative ER/IDR remained 12-month ER/IDR. 45.78% post-operative BIR converted to ER/IDR. Intermediaterisk, T1/T2 staging, non-thyroid capsule invasion, non-multifocal lesion, times of surgery, no abnormal finding on Rx-WBS were predictors for post-operative BIR transferred to 12-month ER/IDR (all P < 0.05). CONCLUSION: Intermediate-risk patients with post-operative ER or IDR might be spared from aggressive RAT, and patients with post-operative BIR could be potential candidates for RAT at higher administered activities (>3.7 GBq, median 5.55 GBq, IQR 4.625 GBq-5.55 GBq), especially in those with less aggressive clinicopathological features who may even obtain ER/IDR at 12-month response.
引用
- Sun Y, Zhao Y, Sun D, et al. Reflective analysis on the current 131I adjuvant therapy indications in intermediate- and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40055209. doi:10.1007/s00259-025-07153-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。